Nataly Beck, MD
Clinical Assistant Professor, Psychiatry and Behavioral Sciences
Bio
As co-founder and co-director of La Clínica Latina, Dr. Nataly Beck is a psychiatrist who is passionate about providing culturally sensitive and compassionate care to patients, especially to those from the Latino community. Originally from Lima, Peru, she immigrated to the US with her family at a young age. She graduated from Yale School of Medicine and completed her psychiatry residency at Vanderbilt University Medical Center. After her first year as an attending at Yale, she began her work at Stanford where she worked in the INSPIRE Clinic for individuals experiencing psychosis and then co-founded La Clínica Latina. She loves the Bay Area and her interests include salsa dancing, playing piano, and spending time with her family.
Clinical Focus
- Psychiatry
- Latino Mental Health
- Young Adults
Academic Appointments
-
Clinical Assistant Professor, Psychiatry and Behavioral Sciences
Professional Education
-
Board Certification: American Board of Psychiatry and Neurology, Psychiatry (2018)
-
Residency, Vanderbilt University Medical Center, General Psychiatry (2018)
-
M.D., Yale University, Medicine (2014)
-
B.S., University of Tennessee, Knoxville, Biomedical Engineering and Biochemistry (2008)
All Publications
-
Assessing the impact of COVID-19 on psychiatric clinical trials.
Journal of psychiatric research
2022; 148: 127-130
Abstract
OBJECTIVE: COVID-19 and associated measures to control the spread of the COVID-19 has significantly impacted clinical research. This study aimed to determine the impact COVID-19 has had on psychiatric clinical trials and to assess whether certain trial areas or trial types were differentially affected.METHODS: We used information from ClinicalTrials.gov, the largest online database of clinical trial information, to examine changes in psychiatric clinical trials from January 2010-December 2020.RESULTS: Clinical trial initiation decreased in 2020, with a year-on-year percent change in trial initiation of -5.4% versus an expected percent change based on forecasting observed trends from 2010 to 2019 of 8.6%. When broken down by disease area, the distribution of trials observed in 2020 was significantly different from the predicted distribution (p<0.00001). The greatest decrease in trial initiation was seen in Schizophrenia-specific trials, with an observed percent change of -29.2% versus an expected percent change of 3.2%. Conversely, anxiety trials saw a significant increase in trial initiation during 2020, with an observed percent change of 24.6% versus an expected percent change of 16.0%. When assessing interventional versus observational studies, data showed a significant increase in initiation of observational psychiatric clinical trials (p<0.05), and a significant decrease in initiation of interventional psychiatric clinical trials (p<0.01). When data was analyzed on a month-by-month time scale, 7/12 months in 2020 showed significant decreases when compared to initiation during matching months over prior years, and a single month, June, showed a significant increase.CONCLUSION: COVID-19 has had significant impacts on the initiation of psychiatric clinical trials over 2020, and this decrease in trial initiation may have long-term impacts on the development and assessment of psychiatric treatments and therapeutics.
View details for DOI 10.1016/j.jpsychires.2022.01.017
View details for PubMedID 35123324
-
Ethical Issues in Psychopharmacology.
Focus (American Psychiatric Publishing)
2021; 19 (1): 53-58
View details for DOI 10.1176/appi.focus.20200043
View details for PubMedID 34483768
-
Ethical Issues in Schizophrenia.
Focus (American Psychiatric Publishing)
2020; 18 (4): 428–31
View details for DOI 10.1176/appi.focus.20200030
View details for PubMedID 33343254
-
Early Psychosis: Diagnosis and Treatment
Current Psychopharmacology
2020
View details for DOI 10.2174/2211556009999200723123322